WOBURN, Mass.--(BUSINESS WIRE)--The most promising areas of translational medical research, including CAR-T cancer therapies and stem cell-based regenerative medicine, require the isolation and purification of large numbers of viable, functional cells. There is growing demand from researchers and clinicians for technologies that provide high viability, enhanced efficiency and scalability to optimize conventional cell separation techniques.
Quad Technologies Inc (“Quad”), developer of a novel cell separation technology, has secured a substantial amount of capital from its Series A round to accelerate development of disruptive cell processing technologies for translational medicine applications. The investment has enabled Quad to launch its MagCloudz™ Streptavidin Cell Separation Kit, which is the first commercially available product incorporating its proprietary QuickGel™ technology. The MagCloudz kit enables straightforward and scalable cell separation with unique magnetic particle dissociation, resulting in complete label free cells for applications including T Cell purification, stem cell isolation, and circulating tumor cell (CTC) separation.
QuickGel is a unique dissolvable hydrogel technology enabling high efficiency purification and release of target cells. Delivering improved cell viability, purity and recovery, QuickGel overcomes limitations of other commercially available cell capture chemistries and enables researchers to simplify their cell separation workflows.
The company, backed by prominent investors including Keswick Ventures, is set to disrupt cell separation and cell therapy.
Ian Ratcliffe from Keswick Ventures explained:
The availability of the MagCloudz kits will revolutionize the cell separation market and provide researchers with the speed, quality and adaptability they need. We are excited to be part of this next phase of growth and looking forward to working with the Quad team to deliver this game-changing solution to market.”
Our MagCloudz kits will truly disrupt existing cell separation and cell therapy research workflows to deliver breakthrough therapies for the clinic and we are delighted to be the first to bring these benefits to market,” explained Sean Kevlahan CEO, “We will continue to strengthen and build on our existing collaborations to solve challenges associated with cell separation and evolve our solutions to meet customer needs in high value applications.”
The company has unveiled its new website to provide information on its QuickGel technology and MagCloudz applications. To find out more about Quad Technologies and how MagCloudz could benefit your cell separation workflow visit www.quadtechnologies.com.
About Quad Technologies
Established in 2013, Quad Technologies is a developer of novel cell separation technology with significant advantages over conventional approaches for the binding and releasing of rare cells. With a product driven business model, the company is committed to answering the needs of researchers working in cell separation applications – www.quadtechnologies.com